FATE1

Fetal and Adult Testis-Expressed 1, encoded by the FATE1 gene in humans, is a protein identified as a cancer-testis antigen (CTA) in hepatocellular carcinomas and gastric and colon cancers.[3][4][5] It is testis-specific in the fetus (aged 6 – 11 weeks). In adults, it is expressed predominantly in the testis and adrenal glands, with some expression in the lungs, heart, kidneys and throughout the brain.[6][7]

FATE1
Identifiers
AliasesFATE1, CT43, FATE, fetal and adult testis expressed 1
External IDsOMIM: 300450 HomoloGene: 57202 GeneCards: FATE1
Gene location (Human)
Chr.X chromosome (human)[1]
BandXq28Start151,716,035 bp[1]
End151,723,194 bp[1]
Orthologs
SpeciesHumanMouse
Entrez

89885

n/a

Ensembl

ENSG00000147378

n/a

UniProt

Q969F0

n/a

RefSeq (mRNA)

NM_033085

n/a

RefSeq (protein)

NP_149076

n/a

Location (UCSC)Chr X: 151.72 – 151.72 Mbn/a
PubMed search[2]n/a
Wikidata
View/Edit Human

FATE1 is member of the Miff protein family, with its C-terminal domain, consisting of a transmembrane domain with a coiled-coil domain, showing high similarity to the mitochondrial fission factor (MFF) protein which is involved in mitochondrial and peroxisomal fission.[5]

Gene location

FATE1 gene in humans is located on the long arm of the X chromosome at region 28, from base pair 150,884,502 to base pair 150,891,617.[3][8]

Mechanism

It has been hypothesized that FATE1 uses its C-terminal transmembrane domain to attach to endoplasmic reticulum (ER) membrane and with its C-terminal coiled-coil domain it interacts with mitochondria.[5]

FATE1 is localized in mitochondria-associated ER membranes (MAM) and modulates ER-mitochondria distance to regulate Ca2+- and drug dependent apoptosis in cancer cells.[5]

FATE1 expression leads to reduction of Ca2+ uptake by mitochondria and therefore decrease in fragmentation of mitochondria, associated with mitochondrial Ca2+ uptake, consequently providing protection against cell death.[9]

Relation to cancer

FATE1 is detectable in all cell lines derived from tumors, but is low or undetectable in telomere immortalized, non-tumorigenic fibroblasts and lung epithelial cells. FATE1 is suggested to be essential for survival of tumor cells as depletion of FATE1 results in viability reduction in melanoma, breast, prostate and sarcoma settings.[10]

Upregulation of FATE1 by a transcription factor steroidogenic factor-1 (SF-1), involved in adrenal and gonadal development as well as in adrenocortical carcinoma, increases ER-mitochondria distance and is utilized by cancer cell to functionally uncouple ER and mitochondria.[5]

Silencing FATE1 gene sensitizes non-small-cell lung cancer cell lines to paclitaxel, a chemotherapeutic drug against many different types of cancers.[11]

Elevated level of FATE1 is found to be associated with higher mortality rate in colorectal cancers, but in non-small-cell lung cancers, elevation of FATE1 alone did not decrease chance of survival, but decreased if RNF183 expression is also increased.[10]

References
  1. GRCh38: Ensembl release 89: ENSG00000147378 - Ensembl, May 2017
  2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. Olesen C, Larsen NJ, Byskov AG, Harboe TL, Tommerup N (November 2001). "Human FATE is a novel X-linked gene expressed in fetal and adult testis". Molecular and Cellular Endocrinology. 184 (1–2): 25–32. doi:10.1016/S0303-7207(01)00666-9. PMID 11694338.
  4. "Entrez Gene: FATE1 fetal and adult testis expressed 1".
  5. Doghman-Bouguerra M, Granatiero V, Sbiera S, Sbiera I, Lacas-Gervais S, Brau F, Fassnacht M, Rizzuto R, Lalli E (September 2016). "FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria". EMBO Reports. 17 (9): 1264–80. doi:10.15252/embr.201541504. PMC 5007562. PMID 27402544.
  6. Dong XY, Su YR, Qian XP, Yang XA, Pang XW, Wu HY, Chen WF (July 2003). "Identification of two novel CT antigens and their capacity to elicit antibody response in hepatocellular carcinoma patients". British Journal of Cancer. 89 (2): 291–7. doi:10.1038/sj.bjc.6601062. PMC 2394243. PMID 12865919.
  7. Yang XA, Dong XY, Qiao H, Wang YD, Peng JR, Li Y, Pang XW, Tian C, Chen WF (February 2005). "Immunohistochemical analysis of the expression of FATE/BJ-HCC-2 antigen in normal and malignant tissues". Laboratory Investigation; A Journal of Technical Methods and Pathology. 85 (2): 205–13. doi:10.1038/labinvest.3700220. PMID 15580283.
  8. Danielle Thierry-Mieg and Jean Thierry-Mieg, NCBI/NLM/NIH. "AceView: Gene:FATE1, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView". www.ncbi.nlm.nih.gov. Retrieved 2018-11-09.
  9. Szabadkai G, Simoni AM, Bianchi K, De Stefani D, Leo S, Wieckowski MR, Rizzuto R (2006-05-01). "Mitochondrial dynamics and Ca2+ signaling". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1763 (5–6): 442–9. doi:10.1016/j.bbamcr.2006.04.002. PMID 16750865.
  10. Maxfield KE, Taus PJ, Corcoran K, Wooten J, Macion J, Zhou Y, Borromeo M, Kollipara RK, Yan J, Xie Y, Xie XJ, Whitehurst AW (November 2015). "Comprehensive functional characterization of cancer-testis antigens defines obligate participation in multiple hallmarks of cancer". Nature Communications. 6 (1): 8840. doi:10.1038/ncomms9840. PMC 4660212. PMID 26567849.
  11. Whitehurst AW, Bodemann BO, Cardenas J, Ferguson D, Girard L, Peyton M, Minna JD, Michnoff C, Hao W, Roth MG, Xie XJ, White MA (April 2007). "Synthetic lethal screen identification of chemosensitizer loci in cancer cells". Nature. 446 (7137): 815–9. doi:10.1038/nature05697. PMID 17429401.

Further reading


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.